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for pregnant women suffering from symptoms of significant hyperacidity and
GERD The number of patients was a limiting factor and more studies need to be
done to establish the therapeutic benefits of combination antacids in pregnant
population.
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OBJECTIVES:To assess the economic impact of introducing LacTest®, a new drug
test which determines the level of hypolactasia in adults and elderly with clin-
ical symptoms of lactose intolerance on the Spanish market. METHODS: A bud-
get impact model was developed using the perspective of the Spanish National
Health System (NHS) with a 4-year time horizon. The model was populated with
data on diagnostic tests for hypolactasia, health care resource utilization, unit
costs and market shares. The potential number of diagnostic tests annually
performed in Spanish hospitals was based on a study estimating the number of
patients with clinical symptoms eligible for a diagnostic test among 45 Spanish
hospitals in Spain. Diagnostic tests included in this study were the hydrogen
breath test plus measurements of capillary blood glucose after an overload of
lactose, intestinal biopsy, fecal pH test, genetic testing and LacTest®. Costs
considered were diagnostic tests, laboratory tests, physician visits and time of
health care personnel. All costs referred to EUR 2012, using a 3% annual discount
rate. Direct medical annual costs per patient with each diagnostic test were
estimated before and after the introduction of LacTest®in order to estimate the
total annual health care costs. RESULTS: The Spanish population with clinical
symptoms of hypolactasia eligible for a diagnostic test was estimated to be
constant at 126,420 during the next four years. Total health care costs were
estimated at €81.7 million without the introduction of LacTest® and at €89.7
million after its introduction. CONCLUSIONS: The introduction of LacTest® only
shows a moderate increase in the total costs for the Spanish NHS. LacTest®
though is a test with a high reliability which decreases the need for repeating
the test and the cause for additional costs as is the case with some of the other
diagnostic tests compared in this study.
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OBJECTIVES: Adherence with 5-aminosalicylic acid (5-ASA) treatments has
been shown to be associated with a reduction in disease relapses in UC patients.
The aim of this budget impact analysis was to explore and quantify how adher-
ence with individual 5-ASA treatments may impact direct medical costs,
through prevented relapses, in the UK. METHODS: A 1-year decision analytic
budget impact model was developed to combine data from a UK-based adher-
ence study of 5-ASA treatments with a chart review study on UC costs by relapse
status in the UK. The model calculates the rates of disease relapses, remissions,
and associated costs, based on adherence rates of each 5-ASA medication. The
model also allows running simulations of relative changes in treatment utiliza-
tion to show the associated budget impact from the perspective of the National
Health Service (NHS). RESULTS: Higher adherence rates (48.3% for MMX
Multi-Matrix System® [MMX] mesalamine; 40.7% for delayed release mesala-
mine [DRM] 800mg; 36.7% for modified release mesalamine [MRM]; 31.8% for
controlled release mesalamine [CRM] 1000mg; 29.7% for controlled release me-
salamine [CRM] 500mg; 29.6% for delayed release mesalamine [DRM] 400mg;
27.8% for balsalazide) were associated with lower hospitalization rates (6.6%;
7.3%; 7.7%; 8.1%; 8.3%; 8.3%; and 8.5%, respectively), lower annual hospitaliza-
tion costs (£330; £365; £383; £404; £414; £414; and £422, respectively), and
lower other medical costs, excluding 5-ASAs (£282; £292; £298; £305; £307; £308;
and £310, respectively). The model showed that a hypothetical move from the
current utilization mix of 5-ASA treatments to the 5-ASA with the highest ad-
herence rate could save the NHS approximately £92,800 annually per
1,000 UC patients. CONCLUSIONS: As non-adherence in UC is associated with
costly medical resource utilization, significant cost-offsets could be achieved
within the NHS by favoring the 5-ASA treatment with the highest adherence
rate.
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OBJECTIVES: Inhibitor development is one of the most important and expensive
adverse event in patients with severe hemophilia A. A different incidence be-
tween second or third generation FVIII determine different resource consump-
tion in long term therapy. The Pass study aimed to assess the break-even point
in patients treated with ADVATE® or with another second or third generation
(FVIII X), considering effects on direct medical cost attributable to different
inhibitors development. METHODS: A model based on Oldenburg 2010 study
population characteristic( 348 Pre Treated Patients; FVIII 2%; no previous in-
hibitor stories) was developed comparing costs generate from ADAVATE® treat-
ment vs “FVIII X”. We considered a time horizon of 5 years and the National
Health System’s (NHS) point of view. In order to assess the validity of the break-
even point estimate, a sensitivity analysis was conducted modifying the per-
centages of patients allocated to prophylaxis or on demand regimen. RESULTS:
According to model results the overall cost during 5 years was: 243,966,787.44€
for ADAVATE® treatment and 223,402,102.06€ for “FVIII X” treatment. To gain
the break-even point between ADAVATE® and “FVIII X”, the number of patients
who should develop inhibitors was 4.98(1.43%) in 5 years. If all patients were
allocated to prophylaxis regimen, to gain the break-even point the number of
patients who should develop inhibitors was 9.68(2.78%). On the other hand for
on demand treatment it should be 1.29(0.37%). CONCLUSIONS: Considering the
high cost generated by inhibitor development and the lack of direct comparing
studies in scientific literature, the Pass Study provided interesting information
for decision makers in order to manage properly patients care. Inhibitor devel-
opment should be more considered during decision process, as an expensive
adverse event in hemophilic A patients treatment. A direct comparing study is
necessary to obtain more consistent results.
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OBJECTIVES: Sequential antyhelicobacter therapy (A) is one of the ways to over-
come Helicobacter pylori (H. pylori) resistance to antibiotics. The aim is com-
pare the cost effectiveness ratio of different schemes of AT of first line: a
sequential therapy (scheme 1) and traditional triple therapy (scheme 2).
METHODS: Cost-effectiveness analysis was used. The schemes and their effi-
cacy were taken from a clinical study which were conducted in a hospital in
Kharkiv (Babak O.J., 2009). This trial involved 63 patients with peptic ulcers of
the duodenum (PUD) associated with H. pylori. Scheme 1: the drugs were pre-
scribed in 2 stages: the first (5 days) - rabeprazole (daily dose (DD) 40 mg),
amoxicillin (DD 2000 mg), the second (5 days) – rabeprazole (DD 40 mg), clari-
thromycin (DD 1000 mg) and bismuthate tripotassium dicitrate (DD 480 mg).
Scheme 2 included of rabeprazole (DD 40 mg), amoxicillin (DD 2000 mg), clari-
thromycin (DD 1000 mg) for 10 days. After administration of both schemes,
the patients received rabeprazole (DD 20 mg) for one month. A criterion of
efficacy was the number of patients (%) with H. pylori eradication: scheme 1 –
96.80%, scheme 2 – 72.00%. For determining the costs of the course of AT per
patient only the costs of the drugs were taken into account. The prices of drugs
were taken from the information system Drugs of Company Morion (Febru-
ary, 2012). The currency ratio of UAH to dollar (USA) on 01.02.12 was 7.98:1.
RESULTS: The costs for the scheme 1 are 170.28 $, for scheme 2 are 202.29$. The
first scheme (ÑER 175.91$) 1.6 times is more cost effective than the scheme 2
(ÑER 280.96$). CONCLUSIONS: The application of sequential antyhelicobacter
therapy can provide effective and economically founded AT PUD in medical
practice.
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OBJECTIVES: Disease related malnutrition (DRM) and its risk are still highly prev-
alent in some patient populations, depending on patients’ diagnoses and age, set-
ting and assessment tools used. DRM is associated with increased morbidity and
mortality, decreased QOL, frequent hospitalizations and increased health care
costs. Moreover, the economic and human costs of malnutrition are avoidable. The
purpose of the study is to estimate cost of DRM in Croatia by assessing direct costs
related to hospitalizations, drug consumption, outpatient care in selected illnesses
(IBD, gastric and lung cancers, chronic renal impairment and COPB). Selection was
based on most evidential relations and available data. Secondary objective was to
calculate and compare the total and per capita medical expenditures for people
with DRM and identify cost saving potential. METHODS: Prevalence-based cost-of-
illness methodology was used to estimate the direct costs (hospital, drugs, physi-
cian and institutional care) and indirect costs (sickness leave) associated with dis-
ease complications related to DRM, as well as patient monitoring and drugs. The
analysis was oriented primary to adult patients receiving hospital in-patient, out-
patient or specified community health-care services. RESULTS: The annual cost
associated with adult malnourished patients in selected illnesses is estimated at
over 100€ million. Most of this cost are in acute hospital (infections, rehospitaliza-
tions) and home care with nutrition support estimated to 10 % of spend. This
cost is substantial, inclining to rise with population aging (older people have in-
creased DRM risk). So far there has been no attention focused on the economic
burden associated with DRM in Croatia or the potential for savings arising from
improved detection and treatment of those at risk. CONCLUSIONS: Screening of
malnutrition as well as better nourishing therapies, in sense of better adherence to
guidelines, would not only evade mortality and morbidity, but save substantial
resources.
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